5 assets in Acute Myeloblastic Leukemia Without Maturation

Therapeutic assets addressing Acute Myeloblastic Leukemia Without Maturation, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Myeloblastic Leukemia Without Maturation	Northwestern University	P3	BBB (78)
Daunomycin Acute Myeloblastic Leukemia Without Maturation	National Cancer Institute (NCI)	P3	BBB (77)
Azacitidine Acute Myeloblastic Leukemia Without Maturation	University of Chicago	P2	BB (69)
Decitabine Acute Myeloblastic Leukemia Without Maturation	Roswell Park Cancer Institute	P3	BB (66)
Gemtuzumab Ozogamicin Acute Myeloblastic Leukemia Without Maturation	National Cancer Institute (NCI)	P2	BB (64)